NCT00505453View on ClinicalTrials.gov

A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 31, 2007

Study Completion Date

August 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Fluviral®

Trial Locations (2)

G1W 4R4

GSK Investigational Site, Québec

J1H 1Z1

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY